Gastro
01 Jan 2013
Probiotic and Crohn’s Disease Study
Probiotics are a food supplement containing living microorganisms, which upon ingestion in certain numbers exert health benefits beyond inherent basic nutrition. They have been shown to reduce intestinal inflammation in the inflammatory bowel diseases, Crohn’s disease (CD) and ulcerative colitis (UC). Probiotics are effective in the treatment of acute pouchitis…
Infections
01 Jan 2013
Study of Viramidine to Ribavirin in Patients with Chronic Hepatitis C Who Are Treatment Naive
The purpose of this study is to determine the safety and effectiveness of viramidine to ribavirin in chronic hepatitis C patients who have never before received treatment. Official Title Randomized, Double-Blind, Multicenter Study to Compare the Safety and Efficacy of Viramidine to Ribavirin in Treatment-Naive Patients With Chronic Hepatitic C…
Cancer
01 Jan 2013
A Feasibility Study to Evaluate Adjuvant Chemoradiotherapy for Gastric Cancer
The purpose of this study is to determine the side-effects and effectiveness of a new type of chemoradiotherapy treatment for patients who have had surgery for stomach cancer. The treatment uses epirubicin, cisplatin, and 5-fluorouracil (ECF) chemotherapy together with radiotherapy. Official Title Conditions Gastric Cancer Study Type Interventional Study Design…
Cancer
01 Jan 2013
Combination chemotherapy of docetaxel, ifosfamide and cisplatin (DIP) in patients with metastatic urothelial cancer
The aim of this study was to evaluate the efficacy and toxicity of a new combination chemotherapy of docetaxel, ifosfamide and cisplatin (DIP) in the treatment of metastatic urothelial cancer. Official Title Combination chemotherapy of docetaxel, ifosfamide and cisplatin (DIP) in patients with metastatic urothelial cancer: a preliminary report. Conditions…
Cancer
01 Jan 2013
Study of irinotecan (CPT-11) combined with fixed dose of 5-fluorouracil (5-FU) adult patients with advanced solid tumours
Advanced solid tumors (gastrointestinal incl. Colorectal, head & neck, others) (1): to find the maximum tolerated dose (MTD) of the combined chemotherapy. (2): to determine the quantitive and qualitative toxic effects, the Dose-limiting toxicity and the recommended dose for phase II trials. (3): to define the safety profile…
Cancer
01 Jan 2013
Irinotecan (CPT-11)-based chemotherapy as induction treatment for advanced colorectal cancer
Advanced colorectal cancer (ACRC) To determine complete resection (R0), response rate, time to progression (TTP) and overall survival (OS) in patients with non-resectable ACRC after being treated with neoadjuvant irinotecan-based chemotherapy. Official Title Conditions Study Type Retrospective analysis Study Design Further Details Treatment Details:Irinotecan 250 mg/m2 i.v. (1h)…
Cancer
01 Jan 2013
Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities
Advanced colorectal cancer. To establish the dose-limiting toxicities and maximum-tolerated dose of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in combination with FOLFIRI, a standard regimen of irinotecan, leucovorin, and infusional 5-fluorouracil (5-FU) in patients with advanced colorectal cancer. Official Title Conditions Study Type…
Blood
01 Jan 2013
Transfusion Medicine/Hemostasis Clinical Research Network
To establish a clinical network which will promote the efficient comparison of new management strategies of potential benefit for children and adults with hemostatic disorders such as idiopathic thrombocytopenia (ITP) and thrombotic thrombocytopenic purpura (TTP). The network also will evaluate new as well as existing blood products and cytokines for…
Cancer
01 Jan 2013
Treatment of non-Hodgkin’s lymphoma with rituximab plus CHOP chemotherapy: 9-year follow-up
The objective of the study was to present long-term follow-up data with updated time to disease progression (TTP) and duration of response (DR) from a multicenter, phase II trial of R-CHOP combination therapy in 40 patients with CD20+, B-cell NHL. Primary endpoints: ORR, PR rate and CR rate; secondary endpoints:…
